The practice of "microdosing" GLP-1 medications like Ozempic, Zepbound, Wegovy, and Mounjaro, which involves taking lower-than-prescribed or less frequent doses, is gaining traction among users seeking to reduce costs, manage side effects, or maintain weight loss. While 15% of surveyed GLP-1 users reported microdosing, with cost savings and side effect management as primary drivers, medical professionals express caution due to a lack of robust clinical evidence supporting its safety and efficacy. Doctors emphasize that the risks associated with these drugs, such as allergic reactions and potential organ issues, are not necessarily dose-dependent. Furthermore, microdosing can lead to dosing errors and may result in uncontrolled blood sugar levels or inconsistent weight management, underscoring the need for professional medical guidance.